SFI
ADMS

Susquehanna Fundamental Investments’s Adamas Pharmaceuticals ADMS Stock Holding History

Susquehanna Fundamental Investments’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-40,590
Closed -$214K – 1972
2021
Q2 		$214K Buy
40,590
+8,990
+28% +$46.5K ﹤0.01% 1465
2021
Q1 		$152K Sell
31,600
-18,240
-37% -$95.2K ﹤0.01% 1427
2020
Q4 		$216K Sell
49,840
-1,000
-2% -$4.28K ﹤0.01% 1348
2020
Q3 		$209K Buy
+50,840
New +$197K 0.01% 1182

Other funds holding ADMS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
CCPM
Cooper Creek Partners Management New York $2.92B AUM 30.49% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Susquehanna Fundamental Investments's ADMS Position: Q3 2021 in Review

Susquehanna Fundamental Investments sold out of Adamas Pharmaceuticals (ADMS) in Q3 2021, closing a stake of 40,590 shares — an estimated $214K sold.

Susquehanna Fundamental Investments first reported a position in ADMS in Q3 2020 and held it in 4 quarters. The position peaked at $216K in Q4 2020. 63 funds tracked by Wall St. Rank hold ADMS as of Q3 2021.

  • Susquehanna Fundamental Investments reported no remaining Adamas Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 40,590 Adamas Pharmaceuticals shares in Q3 2021, an estimated $214K.
  • Susquehanna Fundamental Investments first reported a position in Adamas Pharmaceuticals in Q3 2020 and held it in 4 quarters.
  • Susquehanna Fundamental Investments's Adamas Pharmaceuticals position peaked at $216K in Q4 2020.
  • 63 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q3 2021.

Based on Susquehanna Fundamental Investments's 13F filing for Q3 2021, filed 15 Nov 2021.